Skip to main content

Genetix, Sense Proteomic to Collaborate on Protein Arrays

NEW YORK, Oct. 31 - Genetix Group of New Milton, UK, said Wednesday it had agreed to collaborate with Sense Proteomic to develop a new line of protein arrays.

Genetix said it agreed to work with Sense Proteomic’s of Cambridge, UK, to deploy Sense’s COVET technology in four prototype products. The companies expect to launch the new arrays commercially next year. 

According to Genetix, the COVET technology can express, purify, and array thousands of proteins in a spatially defined format. The proteins arrayed are correctly folded and fully functional, allowing users to more easily identify new drug targets and potential candidates.

“The Genetix Group, like others in the industry, view protein arrays as an area of growth,” Mark Reid, CEO of Genetix, said in a statement. “Sense Proteomic has a unique technology and product portfolio and it is an exciting challenge to help bring these products to market.”

The companies did not disclose the financial terms of the deal.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.